
|Articles|March 15, 2002
InSite obtains rights to optineurin gene
A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron receives another CRL for its Eylea 8 mg
2
Eli Lilly to acquire Adverum Biotechnologies
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
Topcon Healthcare seeks to advance company through acquisition and new investment
5


















































.png)


